I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
The impact of biologic therapies on extra-intestinal manife..:
Francesca Ferretti
;
Maria Camilla Monico
;
Rosanna Cannatelli
...
https://www.frontiersin.org/articles/10.3389/fmed.2022.933357/full. , 2022
Link:
https://doi.org/10.3389/fmed.2022.933357
RT Journal T1
The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:f0a7b803979d42b4bfe8ac61ec4b953d&Exemplar=1&LAN=DE A1 Francesca Ferretti A1 Maria Camilla Monico A1 Rosanna Cannatelli A1 Stefania Carmagnola A1 Marco Vincenzo Lenti A1 Antonio Di Sabatino A1 Francesco Conforti A1 Luca Pastorelli A1 Flavio Caprioli A1 Cristina Bezzio A1 Simone Saibeni A1 Stefano Mazza A1 Maurizio Vecchi A1 Giovanni Maconi A1 Sandro Ardizzone PB Frontiers Media S.A. YR 2022 K1 inflammatory bowel disease K1 extra-intestinal manifestations (EIMs) K1 biologic therapy K1 Vedolizumab K1 TNF inhibitors K1 Ustekinumab K1 Medicine (General) K1 R5-920 JF https://www.frontiersin.org/articles/10.3389/fmed.2022.933357/full LK http://dx.doi.org/https://doi.org/10.3389/fmed.2022.933357 DO https://doi.org/10.3389/fmed.2022.933357 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)